Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nova Thin Film Pharmaceuticals LLC currently faces 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The company's prosecution efforts are distributed across 1 distinct examiner and 1 distinct art unit. This distribution shows that the current workload is centralized within a specific administrative division of the patent office. A focused art unit presence often implies that the technology being patented fits within a well-defined niche of the pharmaceutical sector.
GHALI, ISIS A D is the busiest examiner for the portfolio, with 1 pending office action. This busiest examiner pending figure of 1 represents the total volume of pending actions for the company. Because the portfolio involves 1 distinct art unit, the legal strategy is currently confined to 1 distinct art unit. The company's patent success for its current applications depends on navigating the specific requirements of 1 distinct examiner at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983720 | Oral Soluble Film and Multi-layered Film Including an Oral Soluble Film Layer | GHALI, ISIS A D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17983720 | Oral Soluble Film and Multi-layered Film Including an Oral Soluble Film Layer | GHALI, ISIS A D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17983720 | Oral Soluble Film and Multi-layered Film Including an Oral Soluble Film Layer | GHALI, ISIS A D | 1611 | §103§112 | Non-Final OA | — | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial